803 related articles for article (PubMed ID: 22221944)
1. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
5. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Schleinitz MD; Weiss JP; Owens DK
Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Wu B; Kun L; Liu X; He B
Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
[TBL] [Abstract][Full Text] [Related]
9. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
10. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Hankey GJ
Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
[TBL] [Abstract][Full Text] [Related]
12. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Lanitis T; Kongnakorn T; Jacobson L; De Geer A
Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
[TBL] [Abstract][Full Text] [Related]
14. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
[TBL] [Abstract][Full Text] [Related]
15. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial.
Lamy A; Tong W; Gao P; Chrolavicius S; Gafni A; Yusuf S; Connolly SJ
Can J Cardiol; 2012; 28(1):95-101. PubMed ID: 21983111
[TBL] [Abstract][Full Text] [Related]
16. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
17. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Connolly SJ; Eikelboom JW; Ng J; Hirsh J; Yusuf S; Pogue J; de Caterina R; Hohnloser S; Hart RG;
Ann Intern Med; 2011 Nov; 155(9):579-86. PubMed ID: 22041946
[TBL] [Abstract][Full Text] [Related]
18. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
[TBL] [Abstract][Full Text] [Related]
19. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study.
Lorenzoni R; Lazzerini G; Cocci F; De Caterina R
Am Heart J; 2004 Jul; 148(1):e6. PubMed ID: 15215815
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
Ademi Z; Pasupathi K; Liew D
Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
